Kamada Ltd. develops, produces and markets specialty plasma-derived therapeutics and other biopharmaceutical products for rare and serious conditions. News about KMDA commonly covers financial results and guidance, commercial performance of products such as KAMRAB, GLASSIA, HEPAGAM, VARIZIG, WINRHO and CYTOGAM, and supply arrangements for blood-product markets.
Company updates also address plasma collection operations, including FDA-cleared facilities in Texas, product distribution activity, dividend policy and withholding-tax procedures for ordinary-share distributions. Kamada is traded on Nasdaq and the Tel Aviv Stock Exchange.
Kamada (KMDA) raised its 2026 financial guidance after reporting nine-month revenue of $152.2 million, up 12% year over year. Nine-month net income rose 29% to $21.4 million, while adjusted EBITDA, a non-IFRS earnings measure, increased 20% to $40.9 million. Third-quarter revenue grew 11% to $52.0 million and net income rose 51% to $8.0 million.
The company now expects 2026 revenue of $205 million–$208 million and adjusted EBITDA of $52 million–$54 million, and projects double-digit revenue and profitability growth in 2027. Nine-month operating cash flow was approximately $37.6 million. Cash and cash equivalents totaled $75.3 million at September 30. Kamada declared a $0.14-per-share dividend, approximately $8.0 million, payable during the fourth quarter. Plasma collection continues to ramp up under a three-year, approximately $50 million supply agreement.
Kamada (KMDA) has declared a cash dividend of $0.14 per ordinary share, payable on December 9, 2026. The dividend, equivalent to approximately NIS 0.45 per share, totals approximately $8.0 million. Shareholders of record at the close of business on November 19, 2026, will be eligible. The payment is consistent with the company’s dividend policy. Israeli tax withholding will apply.
Kamada (KMDA) will release its third-quarter and nine-month financial results before U.S. markets open on November 9, 2026. The results cover the periods ended September 30, 2026. Management will host a conference call at 8:30 a.m. Eastern Time that day to discuss the results and answer questions, with a live webcast available.
Kamada (KMDA) announced that CEO Amir London will participate in two investor healthcare conferences during November 2026. He is scheduled to present at the Stifel 2026 Healthcare Conference in New York on November 10 at 10:00 a.m. Eastern Time. He will also attend the Jefferies Global Healthcare Conference in London, held November 16–19. One-on-one investor meetings will be available at both conferences.
Kamada (KMDA) expanded its biosimilar portfolio with the commercial launch of Ustekinumab-Kamada and Enoxaparin-Kamada in Israel, bringing its marketed portfolio to four products. All four were approved and launched as interchangeable with their original reference biologic products.
The company expects at least two additional biosimilars to become commercially available during 2027. It anticipates approximately $4 million in 2026 sales from its existing commercial biosimilar portfolio, growing to approximately $10 million in 2028. By 2030, Kamada expects at least 12 marketed products commercialized in Israel and the Middle East and North Africa, generating approximately $20 million to $25 million in annual revenue.
Kamada (KMDA) reports that current inventory and manufacturing capacity are sufficient to meet increased U.S. demand for KedRAB, following a CDC Health Advisory on a year-over-year rise in nationwide human rabies exposures and use of post-exposure prophylaxis (PEP).
KedRAB, supplied in the United States via Kedrion Biopharma, is a human rabies immune globulin and one of only two FDA-approved anti-rabies immunoglobulin products indicated for PEP treatment in the U.S. Kamada estimates the U.S. rabies immunoglobulin market at approximately $200 million annually. The company highlights its vertically integrated supply chain, long-standing Kedrion partnership, and recent FDA approval of its in-house rabies testing lab as support for reliable, uninterrupted KedRAB supply.
Kamada (KMDA) will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York. CEO Amir London is scheduled to present on Tuesday, September 15, 2026, at 2:30 p.m. Eastern Time and will also be available for one-on-one investor meetings arranged via H.C. Wainwright representatives.
A live webcast and 30-day audio replay of the presentation will be accessible through a specific event link and in the investor relations section of Kamada’s website under Events & Presentations.
Kamada (KMDA) obtained a ruling from the Israel Tax Authority governing Israeli withholding tax on its previously announced cash dividend of $0.17 per share (about $9.8 million in total), expected to be paid on September 17, 2026 to shareholders of record on August 27, 2026.
Under the ruling, Nasdaq shareholders who are residents of a tax-treaty country may be eligible for a Reduced Withholding Tax Rate on the Israeli tax deducted from the dividend, subject to detailed conditions and documentation. On the payment date, Kamada will withhold 25% of the dividend destined for Nasdaq shareholders and remit it to IBI Trust Management, acting as tax processing agent, while 75% will be paid out through the U.S. transfer agent Equiniti Trust Company. Eligible non-Israeli Nasdaq shareholders can apply to the tax agent between the payment date and October 7, 2026 for a refund of excess Israeli withholding, and certain Israeli corporate shareholders may apply for full exemption based on a valid tax authority certificate.
Kamada (NASDAQ: KMDA) declared a cash dividend of $0.17 (≈NIS 0.50) per share, totaling about $9.8 million, on its ordinary shares. The dividend, consistent with the company’s cash dividend policy, will be paid on September 17, 2026 to shareholders of record on August 27, 2026.
According to Kamada, the decision follows record-high financial results and a solid cash position for the first six months of 2026. The company will withhold tax under Israeli law and has applied for an Israel Tax Authority ruling on withholding for non-Israeli shareholders.
Kamada (NASDAQ: KMDA) reported record-high results for the first half and second quarter of 2026. Q2 revenues reached $54.9 million, up 23% year-over-year, with adjusted EBITDA of $14.1 million, a 26% margin, and net income of $9.3 million, up 26%.
First-half 2026 revenues were $100.2 million, up 13%, with adjusted EBITDA of $25.7 million (26% margin) and net income of $13.4 million, up 18%. Operating cash flow for the first six months rose to $17.8 million from $7.5 million. Kamada reaffirmed 2026 guidance of $200–$205 million in revenues and $50–$53 million in adjusted EBITDA, implying 12% and 23% year-over-year growth at midpoints.
The company signed a new three-year plasma supply agreement of approximately $50 million, expects initial sales in Q4 2026, and paid a cash dividend of $0.25 per share (about $14.4 million). Cash and short-term investments totaled $70.1 million as of June 30, 2026.